---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-24-000049"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2024-10-23T23:59:59+00:00"
generated_at: "2026-05-30T11:02:24.943548+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# iBio updates corporate presentation; no specific material changes disclosed

## Summary
- iBio furnished an updated corporate presentation dated October 2024, focused on precision antibody therapeutics powered by machine learning.
- No new financial guidance, pipeline milestones, or operational metrics were provided in the 8-K filing.
- The presentation is furnished under Regulation FD and not incorporated by reference into SEC filings.

## SEC filing metadata
- accession: 0001420720-24-000049
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2024-10-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000049/0001420720-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000049/ibio-20241023x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-24-000049
- JSON: https://secwatch.observer/filing/0001420720-24-000049.json
- Plain text: https://secwatch.observer/filing/0001420720-24-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.